Luca Arecco, Clinical Research Fellow at ESMO, shared on LinkedIn:
“The final version of our Annals of Oncology editorial on the updated results of the OlympiA trial is now freely available.
Here is our perspective on the remaining open questions in the adjuvant treatment of early breast cancer in gBRCA carriers.”
Title: Adjuvant olaparib in germline BRCA carriers: new certainties and remaining open questions from the updated OlympiA results
Authors: L. Arecco, M. Lambertini
Other articles featuring Luca Arecco on OncoDaily.
